Therapixel is a French healthtech company specializing in artificial intelligence solutions for medical imaging, with a particular focus on breast cancer screening. Its flagship product, MammoScreen, is an AI-powered software that assists radiologists in interpreting mammograms more efficiently and with improved accuracy. By providing AI-based scoring and visualization tools, Therapixel helps reduce diagnostic errors, optimize workflow, and support early breast cancer detection.
The company was founded with the vision of creating innovative AI solutions to support radiologists under increasing workload pressure. With breast cancer being the most common cancer among women worldwide, Therapixel’s technology plays a critical role in enhancing early detection rates and improving clinical outcomes.
Features
Therapixel’s core offering is MammoScreen, an AI software designed to evaluate mammograms and assist in breast cancer screening. It operates as a second reader for radiologists, automatically analyzing mammographic images and assigning each case a score from 1 to 10 that indicates the likelihood of cancer.
One of the key features of MammoScreen is its score-based triage system, which helps radiologists prioritize cases with higher suspicion of malignancy. The tool also includes heatmaps and detection markers that highlight suspicious areas within the breast tissue, making it easier to interpret findings quickly and accurately.
The software seamlessly integrates into existing Picture Archiving and Communication Systems (PACS), making it compatible with a wide range of imaging systems used in hospitals and clinics. It supports both 2D and 3D (tomosynthesis) mammography, ensuring broad applicability.
Therapixel’s AI models are trained using extensive datasets from multiple countries, ensuring robustness and generalizability across diverse populations. Additionally, MammoScreen has received FDA clearance in the United States and CE marking in Europe, affirming its clinical safety and reliability.
How It Works
Therapixel’s MammoScreen software is installed within a radiology department’s imaging system and functions as a supportive diagnostic tool. When a new mammogram is captured, the image is automatically sent to MammoScreen, which processes the data using advanced deep learning algorithms.
The AI analyzes the mammographic images and assigns a MammoScreen Score from 1 to 10, where a higher score represents a higher likelihood of cancer presence. Alongside the score, the software provides visual aids like heatmaps and bounding boxes to indicate areas of interest.
Radiologists can then review these insights during their standard workflow. The tool is not designed to replace clinical judgment but to augment it, helping radiologists make more confident decisions and potentially reducing both false positives and false negatives.
MammoScreen is particularly helpful in double-reading workflows, where two radiologists typically evaluate the same mammogram. With AI acting as a consistent second reader, institutions can reduce the need for human double reading while maintaining or improving diagnostic accuracy.
Use Cases
The primary use case for Therapixel’s MammoScreen is in breast cancer screening programs. Hospitals, diagnostic centers, and national health systems can deploy the software to enhance the accuracy and efficiency of mammography interpretation.
MammoScreen is especially valuable in high-volume screening environments where radiologists are required to review hundreds of cases daily. The tool helps prioritize the most urgent cases and supports faster decision-making without compromising diagnostic quality.
Another use case is in healthcare settings facing a shortage of radiologists. By acting as an AI second reader, MammoScreen enables facilities to maintain high-quality screening services with fewer specialists available.
Academic institutions and research hospitals also use MammoScreen to evaluate the performance of AI in clinical practice and explore its potential for training new radiologists.
Pricing
Therapixel does not publicly disclose pricing details on its website. Pricing for MammoScreen is likely tailored based on the size of the healthcare facility, number of users, image volume, and integration needs.
Hospitals or imaging centers interested in deploying the solution are encouraged to contact Therapixel directly via their website to request a personalized quote or product demonstration.
Strengths
One of the major strengths of Therapixel is its specialization in mammography, which allows it to deliver highly focused and clinically validated solutions. MammoScreen is supported by real-world studies and regulatory approvals, including FDA clearance and CE mark, which reinforces its credibility and readiness for clinical use.
The tool’s ease of integration into existing radiology systems makes adoption straightforward, and its visual interface with scores and heatmaps enhances usability for radiologists.
Therapixel also benefits from a strong commitment to scientific research, regularly participating in validation studies and publishing results in peer-reviewed journals. Its solutions are grounded in evidence and tested across diverse populations, increasing their reliability.
Drawbacks
One potential drawback of Therapixel’s MammoScreen is its narrow focus on breast cancer screening. While this allows for depth in its capabilities, it may limit institutions looking for broader AI imaging solutions across multiple modalities or specialties.
Another limitation is the lack of publicly available pricing, which may create a barrier for smaller clinics or facilities interested in budgeting for implementation.
As with any AI tool in healthcare, there can be a learning curve for clinicians unfamiliar with AI-assisted diagnostics. Adoption may require initial training and adjustment of workflow practices.
Comparison with Other Tools
When compared with other AI medical imaging tools like Zebra Medical Vision or ScreenPoint Medical, Therapixel stands out for its single-specialty focus and the simplicity of its MammoScreen Score. While Zebra offers a broader portfolio covering chest X-rays, CTs, and other modalities, Therapixel’s strength lies in its deep expertise in breast imaging.
ScreenPoint Medical’s Transpara is a direct competitor that also focuses on mammography AI. Both tools offer visual scoring and lesion detection, but Therapixel emphasizes usability and seamless PACS integration. The clinical performance of both solutions is comparable, and the choice between them often depends on local needs, system compatibility, and user preference.
Customer Reviews and Testimonials
Therapixel’s MammoScreen has received positive recognition from radiologists and healthcare institutions involved in pilot studies and deployments. Clinical users often cite the clarity of the scoring system, time-saving benefits, and confidence boost in complex cases as major advantages.
While the official website does not include direct user testimonials, published studies and feedback from radiology conferences highlight strong satisfaction with the tool’s clinical relevance and ease of use. MammoScreen has been successfully used in both European and U.S. healthcare settings, indicating its adaptability and acceptance.
Further insights and discussions about the tool can be found in peer-reviewed publications and industry events where Therapixel regularly presents its research and case studies.
Conclusion
Therapixel is a trusted name in AI-powered medical imaging, with MammoScreen offering a practical and reliable solution for breast cancer screening. By providing radiologists with decision-support tools that enhance accuracy and reduce workload, Therapixel contributes meaningfully to early cancer detection and better patient care.
Its regulatory approvals, real-world validation, and focus on usability make it a compelling option for hospitals and diagnostic centers aiming to improve mammography services. While its niche focus may not suit those seeking broader imaging AI tools, Therapixel’s depth and performance in mammography place it among the top-tier solutions in this critical healthcare field.
